Olema Oncology to Present at Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Olema Pharmaceuticals (Nasdaq: OLMA) announced that CEO Sean P. Bohen will present a corporate overview at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:50 p.m. ET. The presentation can be accessed via a live webcast on Olema's website and will be archived for 14 days. Olema Oncology focuses on developing targeted therapies for women’s cancers, with their lead product candidate, OP-1250, currently in Phase 1/2 trials for treating ER-positive breast cancer.

SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42^nd Annual Health Care Conference on Monday, March 7, 2022, at 2:50 p.m. ET (11:50 a.m. PT).

A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days. 

About Olema Oncology 
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

FAQ

When will Olema Pharmaceuticals present at the Cowen 42nd Annual Health Care Conference?

Olema Pharmaceuticals will present on March 7, 2022, at 2:50 p.m. ET.

How can I access Olema's presentation at the Cowen conference?

The presentation will be available via a live webcast on Olema's website.

What is OP-1250 and its current status?

OP-1250 is Olema's lead product candidate, currently in a Phase 1/2 clinical trial for ER-positive breast cancer.

What type of therapies does Olema Oncology focus on?

Olema Oncology specializes in targeted therapies for women’s cancers.

Where is Olema Pharmaceuticals located?

Olema Pharmaceuticals is headquartered in San Francisco with operations in Cambridge, Massachusetts.